If you are experiencing problems downloading PDF or HTML fulltext, our helpdesk recommend clearing your browser cache and trying again. If you need help in clearing your cache, please click here . Still need help? Email help@ingentaconnect.com

A Comparison of the Efficacy of Newly Developed Reversible Inhibitors of Acetylcholinesterase with Commonly Used Pyridostigmine as Pharmacological Pre‐Treatment of Soman‐Poisoned Mice

$48.00 plus tax (Refund Policy)

Download / Buy Article:

Abstract:

Abstract:  The ability of three newly developed reversible inhibitors of acetylcholinesterase (AChE) (K298, K344 and K474) and currently available carbamate pyridostigmine to increase the resistance of mice against soman and the efficacy of antidotal treatment of soman‐poisoned mice was compared. Neither pyridostigmine nor new reversible inhibitors of AChE were able to increase the LD50 value of soman. Thus, the pharmacological pre‐treatment with pyridostigmine or newly synthesized inhibitors of AChE was not able to protect mice against soman‐induced lethal acute toxicity. The pharmacological pre‐treatment with pyridostigmine alone or with K474 was able to slightly increase the efficacy of antidotal treatment (the oxime HI‐6 in combination with atropine) of soman‐poisoned mice, but the increase in the efficacy of antidotal treatment was not significant. The other newly developed reversible inhibitors of AChF (K298, K344) were completely ineffective. These findings demonstrate that pharmacological pre‐treatment of soman‐poisoned mice with tested reversible inhibitors of AChF is not promising.

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.1742-7843.2011.00808.x

Affiliations: Department of Toxicology, Faculty of Military Health Sciences, University of Defense, Hradec Kralove, Czech Republic

Publication date: April 1, 2012

More about this publication?
  • Formerly Pharmacology & Toxicology
Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more